198 related articles for article (PubMed ID: 28280607)
1. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
J Gastrointest Oncol; 2017 Feb; 8(1):39-48. PubMed ID: 28280607
[TBL] [Abstract][Full Text] [Related]
2. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
3. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
[TBL] [Abstract][Full Text] [Related]
4. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer.
Gogate A; Ranjan S; Kumar A; Bhandari H; Papademetriou E; Kim I; Potluri R
Front Oncol; 2023; 13():1119102. PubMed ID: 37205193
[TBL] [Abstract][Full Text] [Related]
5. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
[TBL] [Abstract][Full Text] [Related]
7. Surrogate end points for overall survival in breast cancer trials: A review.
Fiteni F; Bonnetain F
Breast; 2016 Oct; 29():44-8. PubMed ID: 27400447
[TBL] [Abstract][Full Text] [Related]
8. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials.
Petrelli F; Tomasello G; Ghidini M; Lonati V; Passalacqua R; Barni S
HPB (Oxford); 2017 Nov; 19(11):944-950. PubMed ID: 28764887
[TBL] [Abstract][Full Text] [Related]
9. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer.
Petrelli F; Coinu A; Lonati V; Barni S
Int J Colorectal Dis; 2015 Apr; 30(4):447-57. PubMed ID: 25433820
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.
George TJ; Allegra CJ; Yothers G
Curr Colorectal Cancer Rep; 2015; 11(5):275-280. PubMed ID: 26321890
[TBL] [Abstract][Full Text] [Related]
12. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
Korn EL; Sachs MC; McShane LM
Ann Oncol; 2016 Jan; 27(1):10-5. PubMed ID: 26489443
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
[TBL] [Abstract][Full Text] [Related]
14. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
15. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
16. Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome.
Jalilian M; Davis S; Mohebbi M; Sugamaran B; Porter IW; Bell S; Warrier SK; Wale R
J Gastrointest Oncol; 2016 Aug; 7(4):603-8. PubMed ID: 27563451
[TBL] [Abstract][Full Text] [Related]
17. Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited.
Diefenhardt M; Schlenska-Lange A; Kuhnt T; Kirste S; Piso P; Bechstein WO; Hildebrandt G; Ghadimi M; Hofheinz RD; Rödel C; Fokas E;
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954320
[TBL] [Abstract][Full Text] [Related]
18. Individual- and trial-level surrogacy in colorectal cancer.
Buyse M; Burzykowski T; Michiels S; Carroll K
Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
[TBL] [Abstract][Full Text] [Related]
19. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
20. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.
Tomasello G; Petrelli F; Ghidini M; Pezzica E; Passalacqua R; Steccanella F; Turati L; Sgroi G; Barni S
Eur J Surg Oncol; 2017 Sep; 43(9):1607-1616. PubMed ID: 28347525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
